China-based antibiotics developer Tennor Therapeutics picked up $25m in series A capital on Monday from a consortium including R&D services provider WuXi PharmaTech’s Healthcare Fund I.
Venture capital firm Northern Light Venture Capital led the round, while Frontline BioVentures, Oriza Venture Capital and Relativity Healthcare Fund also contributed cash.
Founded in 2013, Tennor is working on a range of antibiotics. Its lead candidate, TNP-2092, is a pill aimed at digestive diseases, primarily those linked to Helicobacter pylori, a bacterium responsible for conditions such as gastric cancer.
The capital injection will allow Tennor to advance TNP-2092 into phase 3 clinical trials, move a second therapy into a phase 1 trial and bring a third candidate into the clinical proof-of-concept stage.
WuXi PharmaTech previously contributed to a series A round of undisclosed size, investing alongside family office 2M Companies, Frontline, Oriza and Newport Healthcare Advisors, according to deals database Pitchbook, though further details are not available.
Zhenkun Ma, founder and chief executive of Tennor, said: “Tennor team is extremely grateful to Northern Light, Frontline BioVentures and other current investors who recognise the value of the company and support our mission.
“With the infusion of the new capital, TenNor is well positioned to deliver the best treatment for Helicobacter pylori and other gastrointestinal tract infections to patients in the coming years.”